Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 8/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 4/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 4/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 1.00 |
| ▸ | MAP3K2 | Q9Y2U5 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.79 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.79 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | MAP3K4 | Q9Y6R4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sr-318 SCHEMBL30797858 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2852950 | 0.81 | MAPK14 (0.67) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2861147 | 0.81 | KDM4E (0.67) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2860213 | 0.80 | KDM4E (0.73) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2852102 | 0.79 | ALDH1A1 (0.67) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2860464 | 0.78 | KDM4E (0.65) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2855315 | 0.78 | KDM4E (0.65) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2850153 | 0.77 | KDM4E (0.63) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL10367088 | 0.75 | ALDH1A1 (0.68) | MAPK14MAPK11DDR1DDR2MAP3K20 | |
| SCHEMBL2854390 | 0.75 | KDM4E (0.61) | MAPK14MAPK11DDR1DDR2MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115195-A1 | CAFFEINE SUSTAINED RELEASE FORMULATION | PROLEVI BIO AB (SE) | 2026-04-30 | — | — | US | disclosed |
| US-12441305-B2 | Vehicle control device | HITACHI ASTEMO, LTD. (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20240254485-A1 | SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF | Hemoshear Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| US-20230391320-A1 | VEHICLE CONTROL DEVICE | HITACHI ASTEMO, LTD. (JP) | 2023-12-07 | — | — | US | disclosed |
| EP-4114522-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | Omeros Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022097387-A1 | VEHICLE CONTROL DEVICE | 日立Astemo株式会社 | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115195-A1 | CAFFEINE SUSTAINED RELEASE FORMULATION | SLC5A7, PDE7A, SLC6A2 | MAPK14 2077/4885MAPK11 592/4885DDR1 2239/4885 |
| US-20240254485-A1 | SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF | SLC20A1, SLC10A1, SLC10A6 | MAPK14 4792/4885MAPK11 4593/4885DDR1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.